Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Winter;9(1):65-70.
doi: 10.22088/cjim.9.1.65.

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran

Hossein Ayatollahi  1 , Mohammad Reza Keramati  1 , Abbas Shirdel  2 , Mohammad Mehdi Kooshyar  2 , Majid Raiszadeh  3 , Sepideh Shakeri  1 , Mohammad Hadi Sadeghian  1
Affiliations

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran

Hossein Ayatollahi et al. Caspian J Intern Med. 2018 Winter.

Abstract

Background: A specific chromosomal abnormality, the Philadelphia chromosome (BCR-ABL fusion), is present in all patients with chronic myeloid leukemia (CML). The b2a2 and b3a2 fusion mRNAs encode p210 fusion protein p210 and e1a2 encode p190. The aim of this study was to evaluate the frequency of BCR-ABL fusion transcript variants in Northeast of Iranian CML patients and to compare the laboratory results of our patients.

Methods: This study was conducted in 85 peripheral blood and bone marrow samples of CML patients. Ribonucleic acid (RNA) was extracted by a commercial kit, RT- PCR for identifying BCR-ABL fusions was carried out by using designed primers and the PCR products were electrophoresed in agarose gels. Finally, statistical analysis was performed for variant frequency identification and their comparison was performed.

Results: All patients examined were positive for BCR/ABL rearrangement. Fusion of b3a2 was detected in 53 (62.35%) patients, b2a2 in 25 (29.41), e1a2 in 1 (1.17%) and coexpression of b3a2 and e1a2 in 6 (7.05%) patients. There were significant differences between the mean age in patients with b3a2 positive ( 44.07 years) and in b3a2 negative group (50.35 years) however, no significant differences were seen between sex and b2a2 (P=0.61), b3a2 (P=0.79) and e1a2 (P=0.20).

Conclusions: This study showed higher frequency b3a2 than b2a2 and e1a2 transcripts in CML patients in Northeast Iran and there was no association between e1a2 transcripts frequencies and monocytosis in peripheral blood.

Keywords: BCR-ABL; Iran; RT-PCR; chronic myeloid leukemia.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

References

    1. Hutchison RE, Schexneider KI. Leukocytic Disorders. In: McPherson RA, Pincus MR, editors. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Pennsylvania: Elsevier Saunders; 2011. p. 616.
    1. Liesveld JL, Lichtman MA. Williams hematology. 8th ed. New York: McGraw-Hill; 2010. pp. 1331–80.
    1. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML) Best Pract Res Clin Haematol. 2009;22:295–302. - PubMed
    1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56. - PubMed
    1. An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–68. - PubMed

LinkOut - more resources